Cousins M J, Umedaly H S
Department of Anesthesia and Pain Management, Royal North Shore, Hospital, St. Leonards, Australia.
Int Anesthesiol Clin. 1996 Fall;34(4):179-93. doi: 10.1097/00004311-199603440-00013.
We hope to have inspired an interest in approaching the pain management issues in this challenging group of patients. Despite significant progress in understanding the pathophysiology of pain, the development of therapeutic options, and the publication and dissemination of guidelines, this progress does not seem to have been adopted into clinical practice. Bonica has stated "for many years I have studied the reasons for inadequate management of postoperative pain, and they remain the same.... Inadequate or improper application of available information and therapies is certainly the most important reason". Let us accept the challenge to re-evaluate pain management in the postoperative neurosurgical patient. Future development may provide enhanced multimodal analgesia with the development of enantioselective NSAIDs and peripherally acting opioids that do not cross the blood-brain barrier. Targeted inhibition of the central neuroplasticity that underlies sensitization, rather than attempts to use pre-emptive analgesics, may be more fruitful. Inhibition of excitatory amino acids may prove beneficial for perioperative neuroprotection and pain management. In addition, longer-acting local anesthetics show significant promise. The importance of understanding the specific benefits available and matching these characteristics to the particular patient is emphasized. Evaluation of outcomes, including morbidity and patient satisfaction, will determine if effective and rational provision of analgesia may indeed be safer than withholding analgesia. However, it is clear that re-evaluation and refinement of conventional therapy is necessary.
我们希望激发大家对处理这类具有挑战性的患者疼痛管理问题的兴趣。尽管在理解疼痛的病理生理学、开发治疗方案以及发布和传播指南方面取得了重大进展,但这些进展似乎并未应用于临床实践。博尼卡曾指出:“多年来我一直在研究术后疼痛管理不足的原因,而这些原因依然如故……现有信息和疗法的应用不足或不当无疑是最重要的原因”。让我们接受挑战,重新评估神经外科术后患者的疼痛管理。随着对映体选择性非甾体抗炎药和不穿过血脑屏障的外周作用阿片类药物的开发,未来的发展可能会提供更强的多模式镇痛。针对导致敏化的中枢神经可塑性进行靶向抑制,而非试图使用超前镇痛,可能会更有成效。抑制兴奋性氨基酸可能对围手术期神经保护和疼痛管理有益。此外,长效局部麻醉剂显示出巨大的前景。强调了了解可用的具体益处并将这些特性与特定患者相匹配的重要性。对包括发病率和患者满意度在内的结果进行评估,将确定有效且合理地提供镇痛是否确实比不给予镇痛更安全。然而,显然有必要对传统疗法进行重新评估和改进。